VPT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) will be supporting a world-first study on maternal cardiovascular changes during pregnancy, which will be conducted at the Mazankowski Alberta Heart Institute in Edmonton, Alberta, Canada.Dr. Lisa Hornberger, Principal Investigator of…...
January 24, 2022
Ventripoint Successfully Completes European Commission QMS Certification Surveillance Audit
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that is it has successfully completed a surveillance audit of its quality assurance system under Medical Device Directive 93/42/EEC (MDD), Annex II with no findings. This is…...
January 7, 2022
Ventripoint Announces Up-Listing to OTCQB Venture Market
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce the Company has received official notification from OTC Markets to up-list to the OTCQB tier effective as of January 7, 2022. The Company will trade on the…...
December 29, 2021
Ventripoint Successfully Renews QMS Certification
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that is it has successfully completed the Medical Device Single Audit Program (MDSAP)re-certification for its Quality Management System (QMS) under ISO 13485:2016 regulations and the FDA Quality…...
December 20, 2021
Ventripoint Appoints Randy AuCoin to Board of Directors
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that Randy AuCoin has joined the Ventripoint Board of Directors.“We are thrilled to have Randy AuCoin join the Board of Directors and utilize his extensive experience in…...
December 6, 2021
Ventripoint Receives Additional Funding to Develop Next Generation of the VMS+, Whole-Heart Analysis System
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to announce that Ventripoint has received additional advisory services and up to $107,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program…...
November 24, 2021
Ventripoint Selected by Life Sciences Ontario as 2021 Success Story
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that Ventripoint will be highlighted as one of Life Sciences Ontario (LSO) 2021 Success Stories (https://lifesciencesontario.ca/reports-and-publications/). The LSO campaign aims to highlight companies and institutions that are…...
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that they have successfully completed a semi-annual follow up inspection of their manufacturing facility by a Nationally Recognized Testing Laboratory (NRTL).A NRTL test mark reflects a manufacturer’s…...
October 25, 2021
Ventripoint Appoints Fiona Fitzgerald to the Board of Directors
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce Fiona Fitzgerald has joined the Board of Directors of the Company.“We are delighted to have Fiona join the Board and look forward to her insights from her…...
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that the East Midlands Congenital Heart Centre in Leicester, UK has received the VMS+3.0 unit.This is the second site in the UK to receive the VMS+3.0 as…...